Treatment of peripheral vascular disease using protein solutions
AssigneeBiomet Biologics, LLC
InventorsMatthew D. Landrigan, Krista Toler, Jennifer E. Woodell-May, David L. Suter
Life of this patent
Estimating the term…
Abstract
Methods of treating peripheral vascular disease comprising administering a protein solution site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII. The solution may also comprise white blood cells, platelets, concentrated bone marrow aspirate, and combinations thereof.
Claims19
A method for improving arterial blood flow in an occluded artery, comprising:
- concentrating whole blood, a fraction of whole blood, white blood cells, bone marrow, a fraction of bone marrow, adipose tissue, a fraction of adipose tissue, or a combination of any of the foregoing, obtained from the subject to form an autologous therapeutic composition;
- and administering the therapeutic composition at or near the ischemic tissue, the therapeutic composition comprising at least about 10,000 pg/ml interleukin-1 receptor antagonist (IL-ira), at least about 15,000 pg/ml soluble interkeukin-1 receptor II (sIL-iRII), and at least two proteins selected from at least about 1,200 pg/ml soluble tumor necrosis factor receptor I (sTNF-RI), at least about 3,000 pg/ml soluble tumor necrosis factor receptor II (sTNF-RII), at least about 130,000 pg/ml insulin-like growth factor-I (IGF-I), at least about 800 pg/ml epidermal growth factor (EGF), at least about 1000 pg/ml hepatocyte growth factor (HGF), at least about 35,000 pg/ml platelet-derived growth factor-AB (PDGF-AB), at least about 10,000 pg/ml PDGF-BB platelet-derived growth factor-BB (PDGF-BB), at least about 500 pg/ml vascular endothelial growth factor (VEGF), and at least about 100,000 pg/ml transforming growth factor-β1 (TGF-β1), wherein the concentration of each selected protein in the therapeutic composition is greater than the concentration of the selected protein in the biological material.
A method for improving arterial blood flow in an occluded artery, comprising topically injecting at or near the site of the ischemic tissue an autologous composition comprising:
- at least 10,000 pg/ml interleukin-1 receptor antagonist (IL-1ra);
- at least 15,000 pg/ml soluble interleukin-1 receptor II (sIL-IRII);
- and at least 1,000 pg/ml hepatocyte growth factor (HGF), wherein the IL-ira, the sTNF-R1 and the sIL-1RII are prepared from whole blood, a fraction of whole blood, bone marrow, a fraction of bone marrow, adipose tissue, a fraction of adipose tissue, or a combination of any of the foregoing.
A method for improving arterial blood flow in an occluded artery, comprising:
- obtaining a cytokine cell suspension from the subject;
- processing the cytokine-cell suspension to produce an autologous protein solution comprising at least 10,000 pg/ml interleukin-1 receptor antagonist (IL-1ra) and at least 15,000 pg/ml soluble interleukin-1 receptor II (sIL-IRII), and hepatocyte growth factor at a concentration of at least about 1,000 pg/ml wherein the ratio of IL-Ira to interleukin-β1 in the composition is greater than 1000, and the ratio of sIL-1RII to IL-βI in the composition is greater than 1;
- and
- administering the autologous protein solution by topical injection at or near the site of the tissue ischemia.
Dependencies are inferred from the claim text.